Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,640 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2.
Barreiro A, Prenafeta A, Bech-Sabat G, Roca M, Perozo Mur E, March R, González-González L, Madrenas L, Corominas J, Fernández A, Moros A, Cañete M, Molas M, Pentinat-Pelegrin T, Panosa C, Moreno A, Puigvert Molas E, Pol Vilarrassa E, Palmada J, Garriga C, Prat Cabañas T, Iglesias-Fernández J, Vergara-Alert J, Lorca-Oró C, Roca N, Fernández-Bastit L, Rodon J, Pérez M, Segalés J, Pradenas E, Marfil S, Trinité B, Ortiz R, Clotet B, Blanco J, Díaz Pedroza J, Ampudia Carrasco R, Rosales Salgado Y, Loubat-Casanovas J, Capdevila Larripa S, Prado JG, Barretina J, Sisteré-Oró M, Cebollada Rica P, Meyerhans A, Ferrer L. Barreiro A, et al. Among authors: blanco j. iScience. 2023 Mar 17;26(3):106126. doi: 10.1016/j.isci.2023.106126. Epub 2023 Feb 2. iScience. 2023. PMID: 36748086 Free PMC article.
Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization.
Pradenas E, Marfil S, Urrea V, Trigueros M, Pidkova T, Pons-Grífols A, Ortiz R, Rovirosa C, Tarrés-Freixas F, Aguilar-Gurrieri C, Toledo R, Chamorro A, Noguera-Julian M, Mateu L, Blanco I, Grau E, Massanella M, Carrillo J, Clotet B, Trinité B, Blanco J. Pradenas E, et al. Among authors: blanco j, blanco i. iScience. 2023 Apr 21;26(4):106457. doi: 10.1016/j.isci.2023.106457. Epub 2023 Mar 20. iScience. 2023. PMID: 36999095 Free PMC article.
β-Cyclodextrins as affordable antivirals to treat coronavirus infection.
Raïch-Regué D, Tenorio R, Fernández de Castro I, Tarrés-Freixas F, Sachse M, Perez-Zsolt D, Muñoz-Basagoiti J, Fernández-Sánchez SY, Gallemí M, Ortega-González P, Fernández-Oliva A, Gabaldón JA, Nuñez-Delicado E, Casas J, Roca N, Cantero G, Pérez M, Usai C, Lorca-Oró C, Alert JV, Segalés J, Carrillo J, Blanco J, Clotet Sala B, Cerón-Carrasco JP, Izquierdo-Useros N, Risco C. Raïch-Regué D, et al. Among authors: blanco j. Biomed Pharmacother. 2023 Aug;164:114997. doi: 10.1016/j.biopha.2023.114997. Epub 2023 Jun 8. Biomed Pharmacother. 2023. PMID: 37311279 Free PMC article.
Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate.
Moros A, Prenafeta A, Barreiro A, Perozo E, Fernández A, Cañete M, González L, Garriga C, Pradenas E, Marfil S, Blanco J, Cebollada Rica P, Sisteré-Oró M, Meyerhans A, Prat Cabañas T, March R, Ferrer L. Moros A, et al. Among authors: blanco j. Vaccine. 2023 Aug 7;41(35):5072-5078. doi: 10.1016/j.vaccine.2023.07.008. Epub 2023 Jul 16. Vaccine. 2023. PMID: 37460353 Free article.
Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates.
Prenafeta A, Bech-Sàbat G, Moros A, Barreiro A, Fernández A, Cañete M, Roca M, González-González L, Garriga C, Confais J, Toussenot M, Contamin H, Pizzorno A, Rosa-Calatrava M, Pradenas E, Marfil S, Blanco J, Rica PC, Sisteré-Oró M, Meyerhans A, Lorca C, Segalés J, Prat T, March R, Ferrer L. Prenafeta A, et al. Among authors: blanco j. iScience. 2023 Jun 28;26(7):107224. doi: 10.1016/j.isci.2023.107224. eCollection 2023 Jul 21. iScience. 2023. PMID: 37502366 Free PMC article.
Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2.
Leal L, Pich J, Ferrer L, Nava J, Martí-Lluch R, Esteban I, Pradenas E, Raïch-Regué D, Prenafeta A, Escobar K, Pastor C, Ribas-Aulinas M, Trinitè B, Muñoz-Basagoiti J, Domenech G, Clotet B, Corominas J, Corpes-Comes A, Garriga C, Barreiro A, Izquierdo-Useros N, Arnaiz JA, Soriano A, Ríos J, Nadal M, Plana M, Blanco J, Prat T, Torroella E, Ramos R; HIPRA-HH-1 study group. Leal L, et al. Among authors: blanco j. NPJ Vaccines. 2023 Sep 29;8(1):147. doi: 10.1038/s41541-023-00736-5. NPJ Vaccines. 2023. PMID: 37775521 Free PMC article.
Macrophage CD5L is a target for cancer immunotherapy.
Sanchez-Moral L, Paul T, Martori C, Font-Díaz J, Sanjurjo L, Aran G, Téllez É, Blanco J, Carrillo J, Ito M, Tuttolomondo M, Ditzel HJ, Fumagalli C, Tapia G, Sidorova J, Masnou H, Fernández-Sanmartín MA, Lozano JJ, Vilaplana C, Rodriguez-Cortés A, Armengol C, Valledor AF, Kremer L, Sarrias MR. Sanchez-Moral L, et al. Among authors: blanco j. EBioMedicine. 2023 May;91:104555. doi: 10.1016/j.ebiom.2023.104555. Epub 2023 Apr 11. EBioMedicine. 2023. PMID: 37054630 Free PMC article.
Post-acute COVID-19 syndrome: a new tsunami requiring a universal case definition.
Lledó GM, Sellares J, Brotons C, Sans M, Antón JD, Blanco J, Bassat Q, Sarukhan A, Miró JM, de Sanjosé S; Multidisciplinary Collaborative Group for the Scientific Monitoring of COVID-19 (GCMSC). Lledó GM, et al. Among authors: blanco j. Clin Microbiol Infect. 2022 Mar;28(3):315-318. doi: 10.1016/j.cmi.2021.11.015. Epub 2021 Nov 24. Clin Microbiol Infect. 2022. PMID: 34826619 Free PMC article. No abstract available.
2,640 results